%0 Journal Article
%T BCL2 Amplicon Loss and Transcriptional Remodeling Drives ABT-199 Resistance in B Cell Lymphoma Models
%J -
%D 2019
%R https://doi.org/10.1016/j.ccell.2019.04.005
%X £¿ Unified genetic and non-mutational mechanisms drive ABT-199 resistance in lymphoma £¿ Rare lymphoma cells having BCL2 amplicon loss are selected during ABT-199 treatment £¿ CDK7-dependent transcriptional reprogramming contributes to ABT-199 resistance £¿ CDK7 inhibition prevents and overcomes ABT-199 resistance in B cell lymphoma model
%U https://www.cell.com/cancer-cell/fulltext/S1535-6108(19)30200-4